Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Operating Expenses across 9 years of filings, most recently posting $87.3 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 4.06% year-over-year to $87.3 million; the TTM figure through Jun 2026 stood at $345.5 million (up 5.89% YoY), while the FY2025 annual figure was $334.1 million, down 2.17% from the prior year.
• Operating Expenses came in at $87.3 million for Q2 2026 at Adaptive Biotechnologies, down from $90.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $116.9 million in Q4 2023 to a low of $79.1 million in Q3 2024.
• Average Operating Expenses over 5 years is $90.9 million, with a median of $90.3 million recorded in 2024.
• Year-over-year, Operating Expenses advanced 27.55% in 2022 and tumbled 30.43% in 2024.
• Over 5 years, Operating Expenses stood at $94.4 million in 2022, then advanced by 23.8% to $116.9 million in 2023, then plunged by 30.43% to $81.3 million in 2024, then gained by 3.88% to $84.5 million in 2025, then gained by 3.4% to $87.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $87.3 million in Q2 2026, $90.1 million in Q1 2026, and $84.5 million in Q4 2025.